Publications by authors named "A Sandrock"
Article Synopsis
- * The study introduces enhanced modeling techniques for neutrino flux and detector response, and it distinguishes between starting (inside) and throughgoing (outside) neutrino interaction events to improve energy resolution.
- * The findings indicate a best-fit point for the 3+1 model with sin²(2θ_{24})=0.16 and Δm_{41}²=3.5 eV², supporting previous studies while showing consistency with no evidence of sterile neutrinos, as reflected
Article Synopsis
- - The study presents a measurement of astrophysical tau neutrinos using 9.7 years of data from the IceCube observatory, identifying seven candidate events with energies between 20 TeV and 1 PeV.
- - Convolutional neural networks were used to analyze simulated event images, helping to estimate the parent tau neutrino energy to be around 200 TeV while facing a background of about 0.5 events primarily from non-tau astrophysical neutrinos.
- - The results confirmed the presence of astrophysical tau neutrinos at a 5σ significance level, aligning with existing IceCube measurements and theoretical predictions regarding neutrino flux and oscillations.
Introduction: Aducanumab selectively targets aggregated forms of amyloid beta (Aβ), a neuropathological hallmark of Alzheimer's disease (AD).
Methods: PRIME was a Phase 1b, double-blind, randomized clinical trial of aducanumab. During the 12-month placebo-controlled period, participants with prodromal AD or mild AD dementia were randomized to receive aducanumab or placebo.
The origin of high-energy cosmic rays, atomic nuclei that continuously impact Earth's atmosphere, is unknown. Because of deflection by interstellar magnetic fields, cosmic rays produced within the Milky Way arrive at Earth from random directions. However, cosmic rays interact with matter near their sources and during propagation, which produces high-energy neutrinos.
View Article and Find Full Text PDFInvestigating Partially Discordant Results in Phase 3 Studies of Aducanumab.
J Prev Alzheimers Dis
March 2023
Objectives: Efficacy and safety results from the EMERGE (NCT02484547) and ENGAGE (NCT02477800) phase 3 studies of aducanumab in early Alzheimer's disease (AD) have been published. In EMERGE, but not in ENGAGE, high-dose aducanumab demonstrated significant treatment effects across primary and secondary endpoints. Low-dose aducanumab results were consistent across studies with non-significant differences versus placebo that were intermediate to the high-dose arm in EMERGE.
View Article and Find Full Text PDF